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ABSTRACT
Background and the purpose of the study: Partition coefficients (log D and log P) and molecular 
surface area (PSA) are potential predictors of the intestinal permeability of drugs. The aim of 
this investigation was to evaluate and compare these intestinal permeability indicators.  
Methods: Aqueous solubility data were obtained from literature or calculated using ACD/Labs and 
ALOGPS. Permeability data were predicted based on log P, log D at pH 6.0 (log D6.0), and PSA.  
Results: Metoprolol’s log P, log D6.0 and a PSA of <65 Å correctly predicted 55.9%, 50.8% 
and 54.2% of permeability classes, respectively. Labetalol’s log P, log D6.0, and PSA correctly 
predicted 54.2%, 64.4% and 61% of permeability classes, respectively. Log D6.0 correlated well 
(81%) with Caco-2 permeability (Papp). Of the list of national essential medicines, 135 orally 
administered drugs were classified into biopharmaceutical classification system (BCS). Of these, 
57 (42.2%), 28 (20.7%), 44 (32.6%), and 6 (4.4%) were class I, II, III and IV respectively. 
Conclusion: Log D6.0 showed better prediction capability than log P. Metoprolol as permeability 
internal standard was more conservative than labetalol.
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INTRODUCTION
Systemic bioavailability of an orally administered 
drug is largely dependent on its physicochemical 
properties and dosage formulation factors (1). 
Sophisticated modeling of the kinetics and 
dynamics of drug processes in the gastrointestinal 
tract subsequently led to the advent of the 
biopharmaceutical classification system (BCS) (2). 
According to the biowaiver, any possible variation 
in the bioavailability of a rapidly dissolving and 
highly soluble drug is attributed to physiological 
conditions rather than formulation and hence there 
is no logic in conducting a bioequivalence testing 
for such formulation (2). BCS offers a framework 
for development of pharmaceutical formulations. 
It has been estimated that the pharmaceutical 
industry can save $35 million annually through 
the applications of BCS (3). Assignment of the 
solubility and permeability classes of a drug is 
a laborious task. Lately, computational models 
to predict aqueous solubility and permeability 
through biological membranes have received 
considerable attention. The use of physicochemical 
properties in predicting in vivo behavior of drugs 
has  many  advantages  including  cost  reduction; 
better control over protocol, reproducibility and 
avoidance of risk presented to human volunteers 
usually encountered in the bioequivalence 
studies (4). Molecular surface properties and 
partition  coefficients  have  been  used  actively 
in construction of quantitative structure activity 
relationship (QSAR) models to predict intestinal 
permeability (2, 5-6).
This study reports for the first time an evaluation and 
comparison of pH-dependent and pH-independent 
n-octanol/water  partition  coefficients  (log  D  and 
log P) and polar surface area (PSA) in prediction 
of intestinal permeability of drugs. The log D  at 
physiologically relevant pH of 6.0 (log D6.0) was 
used to provisionally classify the orally administered 
drugs on the list of national essential medicines 
(NEML) of Pakistan into BCS. 
MATERIAL AND METHODS
The present revision of the NEML contains 335 
medicines of different pharmacological classes (7). 
The highest dose of drug products available in oral 
dosage forms, i.e. oral tablets and capsules, were 
used.  
Solubility
The dose number (Do) was calculated using equation 1: 
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Do =
Mo/Vo
(1)
Cs
Where Mo is the highest dose strength (in mg), Cs is 
the solubility (mg/ml), and Vo equals to 250 ml (8). 
The most conservative data measures were used and 
experimental aqueous solubility data triumphed over 
predicted data. Experimental solubility data were 
obtained from Yalkowsky & He (9) and Drugbank 
(10) which in the later, data were originally from 
(11). Data reporting the pH and temperature at 
which the aqueous solubility of the compound was 
measured were favored. Solubility data for the 
rest of the drugs were calculated using ACD/Labs 
(ACD/Labs,  version  6.0;  Advanced  Chemistry 
Development: Toronto, Canada) and ALOGPS 
(ALOGPS, version 2.1. The Virtual Computational 
Chemistry Laboratory, VCCLAB, Germany). The 
ionization constant (pKa) values were obtained from 
the literature (12). 
Permeability 
Log D and log P are linked through the equations 2 
and 3: 
For acids:
Log D= Log P - Log (1+10 pH-pKa)                        (2)
For bases: 
Log D= Log P - Log (1+10 pKa-pKa)                        (3)
Both log P and log D values were calculated using 
ACD/Labs. Similarly, PSA values were estimated 
using ACD/Labs. 
RESULTS AND DISCUSSION
Previously the orally administered drugs on the 
World Health Organization (WHO) essential 
medicine list (EML) were provisionally classified 
into BCS (13-14). The NEML contained 135 orally 
administered drugs. It has been emphasized that 
the maximal administered dose to solubility ratio 
has a central role in the BCS (15). The NEML 
contained 89 drugs in common with the WHO’s 
EML while in term of doses, only 46 were similar 
(Table 1). 
Solubility correlation and class assignment
Lindenberg  and  colleagues  classified  61  drugs 
with certainty on the basis of reliable practical 
solubility data. A total of 59 drugs were in common 
with Lindenberg’s list (13). ACD/Labs calculated 
solubility and predicted correctly that 51 (86.4%) 
of  the  solubility  classes;  whereas,  data  obtained 
from Drugbank and ALOGPS could correctly 
predict  76.3%  and  78%  of  the  drugs  classified, 
respectively (Supplementary table 1). Solubility 
class assignment was compared to the WHO 
solubility  classification  (16).  Of  the  80  drugs  in 
common, 66 drugs (82.5%) were classified in the 
same solubility classes, whereas, of the 14 drugs 
for which the solubility classes were different, 
6  drugs  were  classified  based  on  incomplete/
inconclusive data and 3 drugs had higher or lower 
doses on the NEML as compared to the WHO’s 
EML (Supplementary table 2). 
Of the 135 drugs on the NEML, 15 (11.1%) drugs 
were  classified  according  to  their  experimental 
solubility data obtained from Yalkowsky & He, of 
which 7 (46.7%) were classified as high soluble drug 
while the rest of 8 (53.3%) were classified as low 
soluble drugs. Additionally, 33 drugs (24.4%) were 
classified based on the solubility data obtained from 
Drugbank. Of these, 29 (87.9%) were classified as 
high solubility drugs while the rest of 4 (12.1%) 
were  classified  as  low  soluble  drugs. The  rest  of 
87 drugs (64.4%) were classified according to the 
ACD/Labs predicted soluble, of which, 66 (75.9%) 
were classified as high soluble drugs and 21 (24.1%) 
drug  were  assigned  to  low  solubility  class  drugs        
(Table 1).
Permeability correlation and class assignment
Kasim and colleagues used metoprolol as internal 
standard indicating high permeability (14). Palm 
and colleagues showed that PSA of <60 Å ensured 
complete intestinal absorption (6); however, Kelder 
and colleagues showed drug intestinal permeation 
predominated by passive diffusion and paracellular 
route for drugs with PSA of less than 120 Å (17). 
When log D6.0 of -1.48, log P of 1.35, and a relaxed 
PSA of ≤65 Å were used to indicate high permeability 
of the 59 drugs in common with the Lindenberg’s 
list, cutoffs correctly predicted the permeability class 
of 30, 33 and 32 drugs (50.8%, 54.2% and 55.9%), 
respectively (Supplementary table 3). The fraction 
absorbed (Fa) of metoprolol (≥95%) is considerably 
even more conservative than permeability criteria 
(≥90%) of the Food and Drug Administration (FDA) 
(18). The use of labetalol as high permeable internal 
standard (Fa ≥90%) was evaluated using log D6.0 of 
-0.42, Log P of 2.31, and PSA of ≤95.6 Å. These 
cutoffs  correctly predicted the permeability class 
of 38, 32, and 36 drugs (64.4%, 54.2% and 61%), 
respectively. 
When WHO’s classification (16) where compared 
with the current classification in table 1; of the 80 
drugs in common, 62 drugs (77.5%) were classified 
in the same permeability classes, whereas, of the 
18 drugs for which the permeability classes were 
different, 11 could be correctly classified by their 
PSA values (Supplementary table 2).
To further verify the suitability of the permeability 
class assignment based on log  D6.0, the Caco-2 
monolayer permeability (Papp) values for a total of 22 
drugs which were in common with a previous work Shawahna et al / DARU 2011 19 (2) 83-99 85
(13)  were  obtained;  these  values  were  basically 
compiled from the literature. The Papp value for 
labetalol was obtained from literature (15). Log 
D6.0 correctly predicted the permeability class for 
18 (81.8%) of the 22 drugs (Supplementary table 
4). Furosemide, hydrochlorthiazide, saquinavir, 
and sulphasalazine were false positives. Similarly, 
the  PSA  of  ≤95.6 Å (PSA of labetalol) correctly 
predicted the permeability class for 18 (81.8%) of 
the 22 drugs (Supplementary table 4). Acetylsalicylic 
acid, atenolol and zidovudine were false positives, 
whereas, digoxin was a false negative. The PSA 
of ≤65 Å correctly predicted only 15 (68.2%) out 
of the 22 drugs compared. In the study of Kasim 
and colleagues, the log P of metoprolol correctly 
predicted 18 of 28 (64%) drugs (5). 
The permeability classes were assigned using log 
D6.0 in comparison to labetalol which was used as 
internal standard. In this classification, 128 (94.8%) 
of the 135 drugs on the NEML were classified, of 
these, 83 (64.8%) were assigned in high permeability, 
while the rest of 45 (35.2%) were assigned in low 
permeability classes. The rest of the 7 (5.2%) were 
classified according to their PSA values. Of these 2 
(28.6%) were classified as high permeability drugs, 
while the rest of 5 (71.4%) were classified as low 
permeability drugs. The final BCS classification of 
the 135 orally administered drugs on the NEML is 
given in table 1 and class distribution is shown in 
figure 1. 
Literature often reported solubility data at room 
temperature. In contrast, the current solubility 
classification  methodology  yielded  an  acceptable 
accuracy of 86.4% and 78.3% for ACD/Labs and 
Drugbank solubility values respectively. Moreover, 
the current classification of solubility criteria were 
conservative since the solubility usually increases as 
a function of temperature, therefore, the solubility 
values at 37°C would be higher than the values used. 
In vivo human permeability investigations are 
expensive  in  terms  of  financial  resources  and 
technical  allocations;  and  moreover  are  time 
consuming.  Several reports described a certain 
correlation between physicochemical properties 
of drug molecules with intestinal absorption (6, 
19-22).  Linnankoski and colleagues suggested 
that passive diffusion predominates the routes of 
intestinal administration for the majority of the 
drugs (20). Although influx and efflux transporters 
have an important role in the absorption of some 
drugs, interestingly, for the majority of drugs the 
active transport is actually negligible (20). Most 
of the drugs available in the market are ionizable 
molecules;  therefore,  passive  diffusion  of  these 
ionizable drugs is partly governed by their pKa 
values. Consequently, log D at physiologically 
relevant  pH  should  better  reflect  the  overall 
distribution (ionized and unionized) of a drug (22, 
23). 
Recently, labetalol was suggested as a better internal 
standard in the permeability comparisons (24). The 
effective intestinal permeability (Papp) is typically 
the parameter reflecting both the rate and extent of 
intestinal  absorption.  In  the  current  classification, 
labetalol was used as internal standard. In accordance 
with results of this study, Winiwater and colleagues 
found a correlation between Papp, log D at pH of 5.5, 
PSA and hydrogen bond donors, the use of log D6.0 
gave better predictions than log P (22). Similarly, 
Linnankoski and colleagues established a correlation 
between the intestinal absorption rate constant (Ka) 
with log D6.0 and PSA (20). 
Figure 1. Biopharmaceutical classification system with drugs on the list of national essential medicines of Pakistan.
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Table 1. BCS classification of the orally administered drugs on the list of national essential medicines (NEML) of Pakistan with their 
therapeutic classes, maximum doses, experimental water solubility, predicted aqueous solubility (ACD/Labs), pH dependent solubility (pKa), 
log D6.0, calculated PSA, and interaction with transporters in the intestine.
Solubility Permeability BCS classification
Drug Therapeutic class
Maximum 
dose (mg)
Do1 Do2 Do3
pKa
Log 
D6.0 ¶
PSA¥ Transporters 
interaction‡
Solubility 
class
Permeability 
class
BCS 
Class
HA† BH+†
Acetylsalicylic acid NSAID 300 NA 0.0012 3.48 -1.24 63.6 Pgp High Low III
Acyclovir Antiviral 200 NA 2.1 9.18 1.89 -1.76 109.83 OATP1, OATP3, OCT1 Low Low IV
Albendazole Anthelmintic 200 NA 13.3 10.46 5.62 2.87 92.31 BCRP Low High II
Allopurinol anti-gout 300 NA 0.03 9.2 2.4 -3.81 74.69 NA High Low III
Amiloride Diuretic 5 NA 0.16 8.58 1.58 1.07 156.79 NA High High I
Aminophylline Antiasthmatic 200 NA 0.00002 NA NA 192 NA High Low III
Amiodarone Antiarrhythmic 200 1.1 9.37 6.29 42.7 MDR1 Low High II
Amitryptyline Antipsychotic 50 NA 0.14 9.24 2.08 3.24 NA High High I
Amlodipine Antihypertensive 5 NA 0.001 8.73 1.43 99.9 MDR1 High High I
Amoxicillin Antibacterial 500 NA 6.66 2.61 6.93 -1.93 158.26 PEPT1 Low Low IV
Amphotericin B Antifungal 100 0.5 3.96 8.13 NA 320 NA High Low III
Ampicillin Antibacterial 500 0.2 2.61 6.79 -1.21 138 PEPT1, OCTN2 High Low III
Anastrozole Anticancer 1 NA 0.008 4.78 0.77 78.3 NA High High I
Atenolol Antihypertensive 100 NA 0.0004 13.88 9.17 -2.73 84.58 MDR1 High Low III
Atropine sulphate Antispasmodic 1 NA 6.76E-06 9.88 -1.52 49.77 NA High Low III
Azathioprine Anticancer 50 1.5 0.25 -0.54 143 NA Low Low IV
Bromocriptine Antiparkinsonism 2.5 NA 0.11 9.61 6.45 4.52 118 MDR1 High High I
Busulphan Anticancer 0.5 NA 1.20E-07 NA -0.52 104 NA High Low III
Baptopril Antihypertensive 50 NA 0.0002 3.82 -2.02 96.41 MDR1: PEPT1 High Low III
Carbamazepine Antiepileptic 200 NA 10 13.94 2.67 46.33 MDR1 Low High II
Carbidopa Antiparkinsonism 25 NA 0.1 3.4 7.91 -2.71 116 NA High Low III
Cefixime Antibacterial 100 NA 0.03 2.1 2.86 -3.72 238 NA High Low III
Cefuroxime Antibacterial 250 NA 3.52 2.59 -4.47 199 PEPT1 Low Low IV
Cephalexin Antibacterial 500 0.04 3.12 6.8 -2.22 138
PEPT1, PEPT2, 
OCTN2
High Low III
Cephradine Antibacterial 500 0.25 3.12 6.99 -1.53 138 OAT1, OCTN2, PEPT1 High Low III
Chlorambucil Anticancer 2 0.01 4.86 3.66 1.52 40.5 MRP1 High High I
Chloramphenicol Antibacterial 250 NA 4.3 11.03 1.02 115.38 NA Low High II
Chloroquine Antimalarial 150 NA 0.02 10.48 1.2 28.16 MDR1 High High I
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Solubility Permeability BCS classification
Drug Therapeutic class
Maximum 
dose (mg)
Do1 Do2 Do3
pKa
Log 
D6.0 ¶
PSA¥ Transporters 
interaction‡
Solubility 
class
Permeability 
class
BCS 
Class HA† BH+†
Table 1 (Cont)
Chlorpheniramine Antiallergic 4 NA 0.0003 9.33 0.49 16.13 NA High High I
Chlorpromazine Antipsychotic 100 NA 0.44 9.43 2.28 31.78 MDR1, OCT1 High High I
Cimetidine Antiulcer 400 NA 0.14 6.73 -1.14 114.19
MDR1, OAT1, OAT3, 
OCT1, OCT3, OCTN2
High Low III
Ciprofloxacin Antibacterial 250 NA 0.77 2.74 8.76 -1.07 72.88 MDR1 High Low III
Clofazimine Antileprosy 100 NA 412.4 6.24 5.72 39.99 MDR1 Low High II
Clomipramine Antipsychotic 25 NA 0.09 9.49 2.58 6.48 MDR1 High High I
Clofazimine Antileprosy 100 NA 412.4 6.24 5.72 39.99 MDR1 Low High II
Cloxacillin Antibacterial 250 NA 0.07 NA -0.81 138.04 PEPT1 High Low III
Colchicine anti-gout 0.5 NA 0.03 NA 0.92 83.09 MDR1, OCT3 High High I
Cyclizine Antihistamine 50 NA 0.2 7.46 1.83 6.5 NA High High I
Cyclophosphamide Anticancer 50 NA 0.002 4.09 0.23 51.38 MDR1 High High I
Cyclosporin Immunosuppressent 100 10 NA NA 279
BCRP, MDR1, MRPs, 
OATP1B1
Low Low IV
Dapsone Antileprosy 50 NA 0.57 1.24 0.94 94.56 NA High High I
Dexamethasone Antiallergic 0.5 NA 0.04 12.14 1.87 94.83 MDR1, OATP1A2 High High I
Diazepam Sedative 10 NA 2 3.4 2.96 32.67 MDR1 Low High II
Didanosine (ddi) Antiretroviral 400 NA 0.81 8.67 1.98 -1.33 83.81 NA High Low III
Digoxin Cardiostimulant 0.25 NA 0.002 13.5 0.85 203.06
MDR1, OATP1B3, 
OATP1C1, OATP4C1, OST
High High I
Diloxanide Anti-Amoebic 500 NA 1.08 NA 1.62 40.54 NA Low High II
Diltiazem
Calcium channel 
blocker
180 NA 0.006 8.91 2.64 84.4 MDR1 High High I
Doxycycline Antibacterial 100 NA 0.54 4.5 9.32 -3.06 181.62 OAT1, OAT3, OAT4 High Low III
Efavirenz Antiretroviral 50 NA 376.6 7.92 4.84 38.33 NA Low High II
Enalapril Antihypertensive 10 NA 0.002 3.75 5.5 -0.12 95.9
MDR1, 
OATP1A2,  PEPT1
High High I
Ergometrine Oxytotic 0.25 NA 0.00018 NA -0.54 68.36 MDR1 High Low III
Ergotamine Antimigraine 1 NA 0.4 9.62 7.2 1.99 118.21 MDR1 High High I
Erythromycin Antibacterial 500 NA 0.08 13.08 8.14 0.72 193.91
MDR1, MRP1, OAT2, 
OATP1A2
High High I
Ethambutol Anti-tuberculosis 400 NA 0.0016 9.6 -3.23 64.52 NA High Low III
Ethosuximide Antiepileptic 250 NA 0.042 9.7 0.38 46.17 NA High High I
Etoposide Anticancer 100 2 9.95 1.96 161 BCRP, MDR1-3,6,7, Low High IIPartition coefficients and molecular surface properties as predictors of drug absorption 88
Solubility Permeability BCS classification
Drug Therapeutic class
Maximum 
dose (mg)
Do1 Do2 Do3
pKa
Log 
D6.0 ¶
PSA¥ Transporters 
interaction‡
Solubility 
class
Permeability 
class
BCS 
Class HA† BH+†
Table 1 (Cont)
Fluoxetine Antipsychotic 20 NA 0.002 10.05 NA 21.3 MDR1 High High I
Flutamide Anticancer 250 NA 0.42 13.12 NA 74.9 NA High High I
Furosemide Diuretic 40 NA 0.02 3.04 0.26 131.01
MRP2, OAT1, OAT3, 
OAT4, OCTN2
High High I
Gemfibrozil Antihyperlipidemia 300 NA 0.12 4.75 2.14 46.5 NA High High I
Glibenclamide Antidiabetic 5 NA 1 NA 2.75 121.98
BSEP, MDR1, MRP1, 
OATP2B1
High High I
Griseofulvin Antifungal 500 NA 2985.07 NA 3.53 71.06 NA Low High II
Haloperidol Antipsychotic 5 NA 0.006 13.9 8.25 0.82 40.54 MDR1 High High I
Hydralazine Antihypertensive 25 NA 0.08 NA 0.56 63.83 NA High High I
Hydrochlorthiazide Diuretic 50 NA 0.48 8.95 -0.07 135.12 NA High High I
Ibuprofen NSAID 600 NA 1.17 4.41 2.12 37.3
MDR1, MRP1, MRP3, 
OAT1-4
Low High II
Imipramine Antipsychotic 25 5.5 9.49 1.85 6.5 MDR1, OCT2, OCT3 Low High II
Indinavir Antiretroviral 400 NA 53.3 5.73 2.76 118.03
MDR1, MRP1, MRP2, 
OATP1A2, OATP1B1
Low High II
Indomethacin NSAID 25 6.25 4.17 0.3 68.5
MDR1, MRP1-8, 
OAT1-4
Low High II
Isoniazid Anti-tuberculosis 300 NA 0.01 11.27 3.79 -0.89 68.01 NA High Low III
Isosorbide dinitrate Antianginal 10 NA 4.82E-05 NA -1.75 58.92 NA High Low III
Labetalol Antihypertensive 200 NA 0.04 7.91 9.2 -0.42 95.6 NA High High I
Lamivudine (3tc) Antiretroviral 150 NA 0.17 13.83 4.41 -0.71 113.45 BCRP, MRP1 High Low III
Levamisole Anthelmintic 40 NA 0.0067 8.81 -0.15 40.9 NA High High I
Levodopa Antiparkinsonism 250 NA 0.09 2.24 9.3 -0.27 103.78 NA High High I
Lisinopril Antihypertensive 20 NA 0.02 2.18 10.51 -1.32 133 MDR1, PEPT1 High Low III
Losartan Antihypertensive 25 NA 0.49 4.24 3.1 0.89 92.5 MDR1, OAT1 High High I
Mebendazole Anthelmintic 100 NA 20 10.29 5.02 2.77 84.08 MDR1 Low High II
Mercaptopurine Anticancer 50 0.03 8.46 2.4 0.37 85.2 MRP4, MRP5 High High I
Metformin Antidiabetic 500 NA 0.002 13.1 -4.31 88.99 OCT1, OCT2 High Low III
Methionine Antidote 250 NA 0.04 2.23 9.26 -2.13 88.6 OCTN2 High Low III
Methotrexate Anticancer 10 NA 6.20E-05 3.54 5.09 NA 211
BCRP, MDR1, MRP1-
7, OAT1-4, OATP1B1, 
OATP1B3, OATP1C1
High Low III
Methyldopa Antihypertensive 500 NA 0.3 2.28 9.3 -2.37 103.78 PEPT1 High Low III
Metoclopramide Antiemetic 10 NA 0.0002 13.28 9.62 -7.8 67.59 NA High Low IIIShawahna et al / DARU 2011 19 (2) 83-99 89
Solubility Permeability BCS classification
Drug Therapeutic class
Maximum 
dose (mg)
Do1 Do2 Do3
pKa
Log 
D6.0 ¶
PSA¥ Transporters 
interaction‡
Solubility 
class
Permeability 
class
BCS 
Class HA† BH+†
Table 1 (Cont)
Metronidazole Anti-Amoebic 400 NA 0.2 2.58 -1.01 78.94 NA High Low III
Morphine Analgesic 30 NA 0.0005 9.72 8.14 -1.77 52.93 MDR1 High Low III
Nalidixic acid Antibacterial 500 NA 0.73 1.2 5.95 0.33 70.5 NA High High I
Nelfinavir Antiretroviral 250 NA 291.54 9.58 7.53 5.44 127.2
BCRP, MDR1, 
OATP1A2, OATP1B1
Low High II
Neostigmine Antidote 15 NA 0.00019 NA -3.03 29.54 MDR1 High Low III
Nevirapine Antiretroviral 200 NA 1.37 10.93 4.74 1.84 58.12 NA Low High II
Niclosamide Anthelmintic 500 NA 1801.8 NA 5.4 95.15 NA Low High II
Nitrofurantoin Antibacterial 100 NA 0.28 7.69 1.2 -0.41 120.73 NA High High I
Nitroglycerin Antianginal 6.4 0.02 NA 2.22 165 NA High High I
Nystatin Antifungal 200 NA 26.6 NA -0.42 319.61 NA Low High II
Omeprazole Antiulcer 20 NA 0.004 9.08 4.61 2.15 96.3 BCRP, MDR1, MRP3 High High I
Paracetamol Analgesic 500 NA 0.19 9.86 0.34 49.33 NA High High I
Penicillamine Antidote 250 NA 0.096 2.13 11.54 -1.57 102.12 NA High Low III
Phenobarbital Antiepileptic 30 NA 0.18 7.88 1.66 75.27 NA High High I
Phenoxymethylpenicillin Antibacterial 500 NA 0.02 2.62 -1.47 121.24 NA High Low III
Phenytoin Antiepileptic 100 NA 4 8.33 2.52 58.2 MDR1, MRP2 Low High II
Prazosin Antihypertensive 2 NA 0.016 6.47 -1.25 107 BCRP, MDR1, OCT1-3 High Low III
Prednisolone Antiallergic 5 NA 0.15 12.47 1.49 94.83 MDR1 High High I
Primaquine Antimalarial 7.5 NA 0.00015 10.38 -0.41 60.17 NA High High I
Procainamide Antiarrythmic 250 NA 0.017 9.86 -1.43 58.4
MDR1, OATP1A2, 
OCT1-3, OCTN1,2
High Low III
Procarbazine Anticancer 50 NA 0.0006 7.46 0.11 53.2 NA High High I
Prochlorperazine Antipsychotic 5 1.34 7.82 2.42 35 NA Low High II
Procyclidine Antiparkinsonism 5 NA 2.03 10.48 0.84 23.5 NA Low High II
Promethazine Antiallergic 25 NA 0.04 8.98 2.04 31.78 MDR1 High High I
Propranolol Antihypertensive 160 NA 0.01 13.84 9.14 0.28 41.49 MDR1, NTCP, OCT2 High High I
Propylthiouracil Anticancer 100 NA 0.2 7.63 0.54 1.36 73.22 NA High High I
Pyrantel Anthelmintic 250 NA 0.012 10.97 -0.49 43.84 NA High Low III
Pyrazinamide Anti-tuberculosis 500 NA 0.09 13.91 -0.37 68.87 NA High High I
Pyridostigmine Muscle relaxant 60 NA 0.0005 NA -4.31 29.54 NA High Low IIIPartition coefficients and molecular surface properties as predictors of drug absorption 90
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Drug Therapeutic class
Maximum 
dose (mg)
Do1 Do2 Do3
pKa
Log 
D6.0 ¶
PSA¥ Transporters 
interaction‡
Solubility 
class
Permeability 
class
BCS 
Class HA† BH+†
Table 1 (Cont)
Quinidine Antiarrythmic 200 5.7 13.05 9.13 1.35 45.6
BSEP, MDR1, OAT3, 
OATP1A2, OATP1B1, 
OCT1,2, OCTN1,2
Low High II
Quinine Antimalarial 200 NA 0.03 13.05 9.13 0.54 45.59
MDR1, OATP1A2, 
OATP1C1, OCT1,2, 
OCTN1,2
High High I
Risperidone Antipsychotic 3 NA 0.017 7.91 1.01 61.9 NA High High I
Rifampicin Anti-tuberculosis 600 NA 1.71 NA -1.75 217
MDR1, MRP1,2,5, 
OATP1A2, OATP1B1, 
OATP1B3, OATP2B1
Low Low IV
Ritonavir Antiretroviral 100 NA 1063.8 11.47 3.48 5.28 202.26
BCRP, MDR1, 
MRP1,2, OATP1A2, 
OATP1B1
Low High II
Salbutamol Antiasthmatic 4 NA 0.000016 9.83 9.22 -2.84 72.72 NA High Low III
Saquinavir Antiretroviral 200 NA 16 NA 2.84 166.75
BCRP, MDR1,2, 
OATP1A2, OATP1B1
Low High II
Selegiline Antiparkinsonism 5 NA 0.78 7.53 1.42 3.2 MDR1 High High I
Spironolactone Diuretic 100 NA 44.3 NA 3.12 85.74 MDR1 Low High II
Stavudine (D4T) Antiretroviral 40 NA 0.009 9.57 -0.86 78.87 NA High Low III
Sulphasalazine Antibacterial 500 NA 0.29 2.88 1.86 0.35 149.69 NA High High I
Tamoxifen Anticancer 20 NA 479.04 8.69 6.2 12.5 BCRP, BSEP, MDR1 Low High II
Theophylline Antiasthmatic 270 NA 0.25 8.6 1.05 -0.18 69.3 NA High High I
Thioacetazone Anti-tuberculosis 50 NA 0.2 NA NA 112 NA High Low III
Thioguanine                     
(6 thioguanine)
Anticancer 40 NA 0.004 7.44 3.09 -0.4 111 MRP4 High High I
Tinidazole Antifungal 500 NA 0.0004 NA -0.27 106 NA High High I
Trifluperazine Antipsychotic 5 NA 1.63 7.82 4.04 35 NA Low High II
Trimethoprim Antibacterial 300 NA 0.17 7.34 -0.42 105.51 MDR1 High High I
Valproic acid Antiepileptic 300 NA 0.005 4.82 -1.65 100.27 OAT3, OCTN2 High Low III
Verapamil Antihypertensive 240 NA 0.85 9.03 2.91 64
BCRP, BSEP, MDR1, 
MRP1-4,7, OATP1A2, 
OCT1, OCTN1,2, PGP
High High I
Warfarin Anti-coagulant 5 NA 0.01 4.5 1.91 63.6 NA High High I
Zalcitabine (DDC) Antiretroviral 0.75 NA 4.96E-07 4.47 -1.51 88.2 NA High Low III
Zidovudine (zDV) Antiretroviral 100 NA 0.1 NA -0.53 91.23 PEPT1 High Low III
1- Do (dose number) calculated from solubility data taken from ref. (9); 2 Do (dose number) calculated from solubility data taken from ref. (10); 3 Do (dose number) 
calculated from predicted solubility data, ACD/Labs; * The maximal dose strength on the list of national essential medicines of Pakistan; † pKa values were taken from ref. 
12; ¶ Calculated log D6.0 values at pH 6 using ACD/Labs; ¥ PSA calculated from ACD/Labs; ‡ Transporter interaction taken from ref. 25;BCRP: Breast cancer resistance 
protein; BSEP: Bile salt export pump; MDR: Multidrug transporter; MRP: Multidrug resistance protein;  NA: not available; OAT: Organic anion transporter; OATP: 
Organic anion-transporting polypeptide; OCTN: Organic cation transporter; OST: Organic solute transporter; PEPT: Peptide transporter; Pgp: P-glycoprotein.Shawahna et al / DARU 2011 19 (2) 83-99 91
Drug Dose (mg)  Do1 D2 D 3 Solubility 
Class 1
Solubility 
Class 2
Solubility 
Class 3
Reliable experimental 
solubilityΘ
Abacavir  300 2.9268293 0.0155844 0.99173554 Low High High High
Acetylsalicylic Acid  500 0.002 0.4347826 1.36986301 High High Low High
Aciclovir 200 2.1052632 0.4938272 0.08810573 Low High High High
Allopurinol  100 0.0101807 0.7029877 0.06802721 High High High High
Amiloride  5 0.1666667   0.01639344 High   High High
Atenolol 100 0.0004 0.0296296 0.93240093 High High High High
Captopril  25 0.0001   0.02212389 High   High High
Carbamazepine  200 10 45.19774 5.26315789 Low Low Low Low
Chloramphenicol 250 4.3478261 0.4 2.1691974 Low High Low High
Chloroquine 150 0.0220345 56.603774 34.2857143 High Low Low High
Cimetidine 200 0.0722022 0.16 0.98039216 High High High High
Cloxacillin 1000 0.2805049 287.76978 75.1879699 High Low Low High
Codeine 30 0.0022822 0.0133333 0.20797227 High High High High
Colchicine  0.5 0.0285714 4.44E-05 0.07246377 High High High High
Cyclophosphamide 25 0.0011682 0.002 0.00662252 High High High High
Dapsone  100 1.1428571 1.0526316 1.4084507 Low Low Low Low
Diazepam  5 1 0.4 1.63934426 High High Low High
Digoxin 0.625 0.0054348   0.01968504 High   High High
Doxycycline  100 0.5405405 0.6349206 0.7751938 High High High High
Ergotamine  1 0.4   0.01793722 High   High High
Fluconazole  50 0.7407407 200 0.14388489 High Low High High
Furosemide 40 0.0230548 26.666667 1.3559322 High Low Low Low
Griseofulvin  250 1492.5373 115.74074 19.8412698 Low Low Low Low
Hydralazine  50 0.1724138   0.07575758 High   High High
Hydrochlorothiazide  25 0.2439024 0.1428571 0.04464286 High High High High
Ibuprofen  400 0.7804878 32.653061 23.3918129 High Low Low Low
Indinavir  400 53.333333 106.66667 33.1950207 Low Low Low Low
Levodopa   250 0.0942507 23.562677 0.3030303 High Low High High
Levonorgestrel  0.75 0.4207574 1.4705882 0.51457976 High Low High High
Levothyroxine  0.1 0.0997506 0.0038095 0.04454343 High High High High
Metformin  500 0.002   0.88888889 High   High High
Methyldopa  250 0.149925 1 0.44247788 High High High High
Metronidazole  500 0.2816901 84.459459 0.008 High Low High High
Nelfinavir  250 291.54519   523.560209 Low   Low Low
Nifedipine  10 1.3333333   2.25988701 Low   Low Low
Nitrofurantoin  100 0.2857143 5.0327126 0.96385542 High Low High Low
Paracetamol 500 0.1966568 0.1428571 0.48192771 High High High High
Penicillamine  250 0.0968054 0.009009 0.21505376 High High High High
Penicillin V  250 0.0125723 1 2.20264317 High High Low High
Phenobarbital  100 0.625 0.3603604 1.44927536 High High Low High
Phenytoin  100 4 12.5 5.62587904 Low Low Low Low
Prednisolone 5 0.1538462 0.0896861 0.08368201 High High High High
Primaquine  15 0.0003165   1.06382979 High   Low High
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Promethazine  25 0.0478469   4.08163265 High   Low High
Propranolol 40 0.0029602 2.2857143 2.01511335 High Low Low High
Propylthiouracil 50 0.1149425 0.1666667 0.42918455 High High High High
Pyrazinamide 400 0.0759734 0.1066667 0.01707577 High High High High
Pyridostigmine  60 0.0005417   0.23076923 High   High High
Riboflavin  5 0.0001868 0.2361275 0.0304414 High High High High
Ritonavir 100 1063.8298   317.460317 Low   Low Low
Salbutamol  4 0.000016 5.3333333 0.00744186 High Low High High
Saquinavir  200 16   323.88664 Low   Low Low
Stavudine  40 0.0091376 0.016 0.00395062 High High High High
Sulfamethoxazole  400 1.509434 2.6229508 3.48583878 Low Low High Low
Theophylline  300 0.2836879 0.24 0.05240175 High High High High
Thiamine  50 0.0009126 0.0004 13.0718954 High High Low High
Trimethoprim  200 0.1152738 0.0661157 1.30081301 High High Low Low
Valproic Acid  500 0.0091258 0.004 130.718954 High High Low Low
Zidovudine  300 0.3243243 0.024 0.07361963 High High High High
1-Do (dose number) calculated from predicted solubility data, ACD/Labs; 2 Do (dose number) calculated from solubility data obtained from DrugBank 
database; 3 Do (dose number) calculated from predicted solubility data, ALOGPS; Θ Reliable experimental solubility, were taken from ref. 13.
Drug Dose (mg)  D1 D2 D3 Solubility 
Class 1
Solubility 
Class 2
Solubility 
Class 3
Reliable experimental 
solubilityΘ
Supplementary table 1 (Cont)
Drug
WHO¶ 
Dose 
(mg) 
NEML 
Dose (mg) 
WHO¶ 
Solubility class
NEML 
Solubility class
Comment
WHO ¶ 
Permeability 
class
NEML 
Permeability 
class
Comment
Acetylsalicylic acid 500 300 High High   High Low
Classified  as  low 
permeability  
drug based on 
reliable  data*; 
log  D6.0 indicated 
low permeability, 
whereas, PSA was 
lower than that of 
labetalol
Aciclovir 200 200 High Low   Low Low  
Albendazole 400 200 Low Low   inconclusive High  
Allopurinol 100 300 High High   High Low
Classified  as  low 
permeability  
drug based on 
reliable  data*; 
log D6.0  indicated 
low permeability, 
whereas, PSA was 
lower than that of 
labetalol
Amiloride 5 5 High High   High High  
Amitriptyline 25 50 High High   High High  
Supplementary table 2: Solubility and permeability classification comparing the list of national essential medicines (NEML) of Pakistan 
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Amlodipine 5 5 High High   High High  
Amoxicillin 500 500 High Low
classified as high 
solubility based 
on incomplete 
data*
High Low
Classified as high 
permeability based 
on incomplete 
data*; both log D6.0 
and PSA indicated 
low permeability
Atenolol 100 100 High High   Low Low  
Carbamazepine 200 200 Low Low   High High  
Cefixime 400 100 Low High
NEML dose is 
lower than that 
of WHO
inconclusive Low  
Chloramphenicol 250 250 High Low   Low High
Classified  as  low 
permeability based 
on  reliable  data*; 
PSA can indicate 
low permeability
Chloroquine  150 150 High High   High High  
Chlorphenamine  4 4 High High   inconclusive High  
Chlorpromazine  100 100 High High   inconclusive High  
Ciprofloxacin  250 250 High High   inconclusive Low  
Clomipramine  25 25 High High   inconclusive High  
Cloxacillin 1000 250 High High   Low Low  
Dapsone 100 50 Low High
NEML dose is 
lower than that 
of WHO
High High  
Diazepam 5 10 High Low
NEML dose is 
higher than that 
of WHO
High High  
Didanosine 400 400 High High   Low Low  
Digoxin 0.25 0.25 High High   High High  
Diloxanide 500 500 Low Low   inconclusive High  
Doxycycline  100 100 High High   High Low
Classified  as  low 
permeability drug 
based on reliable 
data*;    both  log 
D6.0 and PSA 
indicated low 
permeability
Efavirenz 200 50 Low Low   inconclusive High  
Enalapril 2.5 10 High High   Low High
Both log D6.0 and 
PSA indicated 
high permeability
Drug
WHO¶ 
Dose 
(mg) 
NEML 
Dose (mg) 
WHO¶ 
Solubility class
NEML 
Solubility class
Comment
WHO ¶ 
Permeability 
class
NEML 
Permeability 
class
Comment
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Erythromycin  250 500 Low High
classified as low 
solubility based 
on incomplete 
data*
Low High
Classified  as  low 
permeability based 
on incomplete 
data*;  PSA  can 
indicate low 
permeability
Ethambutol  400 400 High High   Low Low  
Furosemide 40 40 Low High   inconclusive High  
Glibenclamide 5 5 Low High
classified as low 
solubility based 
on inconclusive 
data*
inconclusive High  
Griseofulvin 250 500 Low Low   High High  
Haloperidol 2 5 inconclusive High   Low High  
Hydralazine  50 25 High High   Low High
Classified  as  low 
permeability drug 
based on reliable 
data*;    both  log 
D6.0 and PSA 
indicated high 
permeability
Hydrochlorothiazide 25 50 High High   Low High
Classified  as  low 
permeability drug 
based on reliable 
data*;    PSA  can 
indicate low 
permeability
Ibuprofen 400 600 Low Low   High High  
Indinavir sulfate 400 400 Low Low   inconclusive High  
Isoniazid 300 300 High High   inconclusive Low  
Isosorbide dinitrate 5 10 High High   inconclusive Low  
Lamivudine 150 150 High High   High Low
Both log D6.0 and 
PSA indicated low 
permeability
Levamisole  150 40  High  High   inconclusive High  
Levodopa 250 250 High High   High High  
Carbidopa 25 25 High High   inconclusive Low  
Mebendazole 500 100 Low Low   inconclusive High  
Dl-methionine 250 250 High High   High Low
Classified as high 
permeability based 
on incomplete 
data*;  PSA  can 
indicate high 
permeability
Metformin  500 500 High High   Low Low  
Methyldopa 250 500 High High   Low Low  
Drug
WHO¶ 
Dose 
(mg) 
NEML 
Dose (mg) 
WHO¶ 
Solubility class
NEML 
Solubility class
Comment
WHO ¶ 
Permeability 
class
NEML 
Permeability 
class
Comment
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Metoclopramide  10 10 High High   Low Low  
Metronidazole  500 400 High High   High Low
Classified as high 
permeability drug 
based on reliable 
data*;    PSA  can 
indicate low 
permeability
Morphine  10 30 High High   inconclusive Low  
Nelfinavir  250 250 inconclusive Low   inconclusive High  
Neostigmine  15 15 High High   Low Low  
Nevirapine  200 200 Low Low   High High  
Niclosamide 500 500 Low Low   inconclusive High  
Nitrofurantoin  100 100 Low High   High High  
Nystatin  200 200 inconclusive Low   inconclusive High  
Paracetamol  500 500 High High   High High  
Penicillamine  250 250 High High   Low Low  
Phenobarbital 100 30 High High   High High  
Penicillin v 250 500 High High   High Low
Classified as high 
permeability drug 
based on reliable 
data*;    both  log 
D6.0 and PSA 
indicated low 
permeability
Phenytoin  100 100 Low Low   High High  
Prednisolone 25 5 High High   High High  
Primaquine  15 7.5 High High   High High  
Promethazine 25 25 High High   High High  
Propranolol 40 160 High High   High High  
Propylthiouracil  50 100 High High   High High  
Pyrantel  250 250 Low High
classified as low 
solubility based 
on inconclusive 
data*
inconclusive Low  
Pyrazinamide  400 500 High High   inconclusive High  
Quinine  300 200 High High   High High  
Rifampicin  300 600 Low Low   High Low
Classified as high 
permeability based 
on incomplete 
data*; both log D6.0 
and PSA indicated 
low permeability
Ritonavir  100 100 Low Low   inconclusive High  
Salbutamol  4 4 High High   High Low  
Saquinavir  200 200 Low Low   inconclusive High  
Spironolactone  25 100 inconclusive Low   inconclusive High  
Drug
WHO¶ 
Dose 
(mg) 
NEML 
Dose (mg) 
WHO¶ 
Solubility class
NEML 
Solubility class
Comment
WHO ¶ 
Permeability 
class
NEML 
Permeability 
class
Comment
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Stavudine (d4t) 40 40 High High   High Low
PSA can indicate 
high permeability
Sulphasalazine  500 500 Low High
classified as low 
solubility based 
on inconclusive 
data*
Low High
Inconclusive  
data*;  PSA  can 
indicate low 
permeability
Trimethoprim  200 300 Low High   High High  
Valproic acid  500 300 High High   High Low
Classified as high 
permeability drug 
based on reliable 
data*;    both  log 
D6.0 and PSA 
indicated low 
permeability
Verapamil  80 240 Low High
classified as low 
solubility based 
on inconclusive 
data*
High High  
Warfarin 5 5 High High   High High  
Zidovudine (zdv) 300 100 High High   High Low
Classified as high 
permeability drug 
based on reliable 
data*;      PSA  can 
indicate high 
permeability
* Ref. (13); ¶ Ref. (16)
Drug
WHO¶ 
Dose 
(mg) 
NEML 
Dose (mg) 
WHO¶ 
Solubility class
NEML 
Solubility class
Comment
WHO ¶ 
Permeability 
class
NEML 
Permeability 
class
Comment
Supplementary table 2 (Cont)
Drug Log P  Log D6.0  PSA 
Internal standard: Metoprolol Internal standard: Labetalol 
Reliable 
experimental 
solubilityΘ
Log P cutoff 
“1.35”
Log D6.0 
cutoff “-1.48”
PSA cutoff 
“65”
Log P cutoff 
“2.31”
Log D6.0 
cutoff “-0.42”
PSA cutoff 
“95.6”
Abacavir  0.72 0.03 96.95 Low Low Low Low High Low Low
Acetylsalicylic Acid  1.19 -1.24 63.6 Low Low High Low Low High Low
Aciclovir -1.76 -1.76 109.83 Low Low Low Low Low Low Low
Allopurinol  -1.33 -3.81 74.69 Low Low Low Low Low High Low
Amiloride  1.08 1.07 156.79 Low Low Low Low High Low High
Atenolol 0.1 -2.73 84.58 Low Low Low Low Low High Low
Captopril  0.27 -2.02 96.41 Low Low Low Low Low Low Low
Carbamazepine  2.67 2.67 46.33 High High High High High High High
Chloramphenicol 1.02 1.02 115.38 Low Low Low Low High Low Low
Chloroquine 4.69 1.2 28.16 High Low High High High High High
Cimetidine 0.26 -1.14 114.19 Low Low Low Low Low Low Low
Cloxacillin 2.53 -0.81 138.04 High Low Low High Low Low Low
Codeine 1.2 -0.99 41.93 Low Low High Low Low High Low
Colchicine  0.92 0.92 83.09 Low Low Low Low High High Low
Cyclophosphamide 0.23 0.23 51.38 Low Low High Low High High High
Supplementary table 3: Comparison of Permeability prediction based on log P, log D6.0 and PSA, by using  metoprolol or labetalol as 
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Dapsone  0.94 0.94 94.56 Low Low Low Low High High High
Diazepam  2.96 2.96 32.67 High High High High High High High
Digoxin 0.85 0.85 203.06 Low Low Low Low High Low High
Doxycycline  -0.54 -3.06 181.62 Low Low Low Low Low Low High
Ergotamine  3.58 1.99 118.21 High High Low High High Low Low
Fluconazole 0.5 0.5 71.79 Low Low Low Low High High High
Furosemide 3 0.26 131.01 High Low Low High High Low Low
Griseofulvin  3.53 3.53 71.06 High High Low High High High High
Hydralazine  1 0.56 63.83 Low Low High Low High High Low
Hydrochlorothiazide  -0.07 -0.07 135.12 Low Low Low Low High Low Low
Ibuprofen  3.72 2.12 37.3 High High High High High High High
Indinavir  2.88 2.76 118.03 High High Low High High Low Low
Levodopa   -0.22 -0.27 103.78 Low Low Low Low High Low High
Levonorgestrel  3.92 3.92 37.3 High High High High High High High
Levothyroxine  5.93 3.38 92.78 High High Low Low High High Low
Metformin  -2.31 -4.31 88.99 Low Low Low Low Low High Low
Methyldopa  0.12 -2.37 103.78 Low Low Low Low Low Low Low
Metronidazole  -1.01 -1.01 78.94 Low Low Low Low Low High High
Nelfinavir  6.98 5.44 127.2 High High Low Low High Low Low
Nifedipine  2.97 2.96 110.45 High High Low High High Low High
Nitrofurantoin  -0.4 -0.41 120.73 Low Low Low Low High Low High
Paracetamol 0.34 0.34 49.33 Low Low High Low High High Low
Penicillamine  0.93 -1.57 102.12 Low Low Low Low Low Low Low
Penicillin V  1.88 -1.47 121.24 High Low Low Low Low Low High
Phenobarbital  1.67 1.66 75.27 High High Low Low High High High
Phenytoin  2.52 2.52 58.2 High High High High High High High
Prednisolone 1.49 1.49 94.83 High High Low Low High High High
Primaquine  2.67 -0.41 60.17 High Low High High High High High
Promethazine  4.78 2.04 31.78 High High High High High High Low
Propranolol 3.1 0.28 41.49 High Low High High High High High
Propylthiouracil 1.37 1.36 73.22 High Low Low Low High High Low
Pyrazinamide -0.37 -0.37 68.87 Low Low Low Low High High High
Pyridostigmine  -4.31 -4.31 29.54 Low Low High Low Low High Low
Riboflavin  -2.02 -3.48 155.05 Low Low Low Low Low Low High
Ritonavir 5.28 5.28 202.26 High High Low Low High Low Low
Salbutamol  0.01 -2.84 72.72 Low Low Low Low Low High High
Saquinavir  4.44 2.84 166.75 High High Low High High Low Low
Stavudine  -0.86 -0.86 78.87 Low Low Low Low Low High High
Sulfamethoxazole  0.89 0.49 106.6 Low Low Low Low High Low High
Theophylline  -0.17 -0.18 69.3 Low Low Low Low High High High
Thiamine  -1.61 -1.65 100.27 Low Low Low Low Low Low Low
Trimethoprim  0.79 -0.42 105.51 Low Low Low Low High Low High
Valproic Acid  -1.61 -1.65 100.27 Low Low Low Low Low Low High
Zidovudine  -0.53 -0.53 91.23 Low Low Low Low Low High High
Drug Log P  Log D6.0  PSA 
Internal standard: Metoprolol Internal standard: Labetalol 
Reliable 
experimental 
solubilityΘ
Log P cutoff 
“1.35”
Log D6.0 
cutoff “-1.48”
PSA cutoff 
“65”
Log P cutoff 
“2.31”
Log D6.0 
cutoff “-0.42”
PSA cutoff 
“95.6”
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Drug  Papp**
Permeability 
class Log D6.0
¶ Permeability 
class Prediction
PSA 
cutoff 
“95.6”
Prediction
PSA 
cutoff 
“65”
Prediction
Log P 
cutoff 
“1.35”
Prediction
Log P 
cutoff 
“2.31”
Prediction
Acetylsalicylic acid 2.4× 10−6 Low -1.24 Low c High fp High fp Low c Low c
Atenolol  5.3× 10−7 Low -2.73 Low c High fp Low c Low c Low c
Carbamazepine  2.15× 10−5 High 2.67 High c High c High c High c High c
Chlorpheniramine 1.6× 10−5 High 0.49 High c High c High c High c High c
Cimetidine  1.37× 10−6 Low -1.14 Low c Low c Low c Low c Low c
Dexamethasone 2.34× 10−5 High 1.87 High c High c Low fn High c Low fn
Diazepam  3.34× 10−5 High 2.96 High c High c High c High c High c
Digoxin 5× 10−5 High 0.85 High c Low fn Low fn Low fn Low fn
Diltiazem 4.9× 10−5 High 2.64 High c High c Low fn High c High c
Furosemide  3.33× 10−6 Low 0.26 High fp Low c Low c High fp High fp
Griseofulvin  3.68× 10−5 High 3.53 High c High c Low fn High c High c
Hydrochlorthiazide  5.1× 10−7 Low -0.07 High fp Low c Low c Low c Low c
Ibuprofen 5.25× 10−5 High 2.12 High c High c High c High c High c
Indomethacin 2.04× 10−5 High 0.3 High c High c Low fn High c High c
Labetalol 1.5× 10−5 Ref -0.42 High c High c Low fn High c High c
Phenytoin  2.67× 10−5 High 2.52 High c High c High c High c High c
Propranolol 2.75× 10−5 High 0.28 High c High c High c High c High c
Quinine  2.04× 10−5 High 0.54 High c High c High c High c High c
Saquinavir  5.5× 10−7 Low 2.84 High fp Low c Low c High fp High fp
Sulphasalazine  1.29× 10−7 Low 0.35 High fp Low c Low c High fp High fp
Theophylline  4.47× 10−5 High -0.18 High c High c Low fn Low fn Low fn
Verapamil  2.63× 10−5 High 2.91 High c High c High c High c High c
Zidovudine 6.93× 10−6 Low -0.53 Low c High fp Low c Low c Low c
¶ Calculated log D values at pH 6 using ACD/Labs; ** Taken from ref. 15; Ж taken from ref. 19; 
Ref: reference; c: correct; fp: false positive; fn: false negative.
Supplementary table 4: Permeability data correlation: Log D6.0  ACDLabs, PSA and experimental Caco-2 permeability coefficient 
(Papp).
CONCLUSION
Within the limitations of our investigation, the 
following conclusions can be drawn. First, log D6.0 
showed better prediction capability than log P. 
Second, metoprolol was conservative permeability 
internal standard as compared to labetalol. Finally, 
models combining log D and PSA can have the best 
permeability prediction capabilities.
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